AK104
AK104 is a pharmaceutical drug with 47 clinical trials. Currently 23 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
13
Early Stage
26
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
80.0%
12 of 15 finished
20.0%
3 ended early
23
trials recruiting
47
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Clinical Trials (47)
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
AK104 for Recurrent or Metastatic Vulvar Cancer
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 47